8DI2 | pdb_00008di2

Site 2 insulin receptor binding peptide IM459N21

• PDB DOI: https://doi.org/10.2210/pdb8DI2/pdb
• BMRB: 31030

• Classification: SIGNALING PROTEIN
• Organism(s): synthetic construct
• Mutation(s): No 


• Deposited: 2022-06-28 Released: 2022-11-09 
• Deposition Author(s): Lawrence, M.C., Hu, H., Martinez, F.J., Espinosa, J.F.
• Funding Organization(s): Not funded

---

Experimental Data Snapshot

• Method: SOLUTION NMR
• Conformers Calculated: 16 
• Conformers Submitted: 16 
• Selection Criteria: all calculated structures submitted 

Literature

Activation of the human insulin receptor by non-insulin-related peptides.

Kirk, N.S., Chen, Q., Wu, Y.G., Asante, A.L., Hu, H., Espinosa, J.F., Martinez-Olid, F., Margetts, M.B., Mohammed, F.A., Kiselyov, V.V., Barrett, D.G., Lawrence, M.C.

(2022) Nat Commun 13: 5695-5695

• PubMed: 36171189 
• DOI: https://doi.org/10.1038/s41467-022-33315-8
• Primary Citation Related Structures: 
  7U6D, 7U6E, 8DI2


• PubMed Abstract: 
  

  The human insulin receptor signalling system plays a critical role in glucose homeostasis. Insulin binding brings about extensive conformational change in the receptor extracellular region that in turn effects trans-activation of the intracellular tyrosine kinase domains and downstream signalling. Of particular therapeutic interest is whether insulin receptor signalling can be replicated by molecules other than insulin. Here, we present single-particle cryoEM structures that show how a 33-mer polypeptide unrelated to insulin can cross-link two sites on the receptor surface and direct the receptor into a signalling-active conformation. The 33-mer polypeptide engages the receptor by two helical binding motifs that are each potentially mimicable by small molecules. The resultant conformation of the receptor is distinct from-but related to-those in extant three-dimensional structures of the insulin-complexed receptor. Our findings thus illuminate unexplored pathways for controlling the signalling of the insulin receptor as well as opportunities for development of insulin mimetics.

---

Organizational Affiliation: 
• WEHI, 1G Royal Parade, Parkville, VIC, 3052, Australia.
Department of Medical Biology, Faculty of Medicine, Dentistry and Health Sciences, University of Melbourne, Parkville, VIC, 3050, Australia.
Eli Lilly and Company, Lilly Corporate Center, Indianapolis, IN, 46285, USA.
Advanced Testing Laboratories, Blue Ash, OH, 45242, USA.
Centro de Investigación Lilly S.A., Avda. de la Industria 30, Alcobendas, Madrid, 28108, Spain.
Eli Lilly and Company, Lilly Corporate Center, Indianapolis, IN, 46285, USA. [e-mail].
Eli Lilly and Company, Lilly Corporate Center, Indianapolis, IN, 46285, USA. [e-mail].
WEHI, 1G Royal Parade, Parkville, VIC, 3052, Australia. [e-mail].
Department of Medical Biology, Faculty of Medicine, Dentistry and Health Sciences, University of Melbourne, Parkville, VIC, 3050, Australia. [e-mail].

Biological Assembly 1  

Global Symmetry: Asymmetric - C1 
Global Stoichiometry: Monomer - A1 

Biological assembly 1 assigned by authors.

Biological Assembly Evidence: mass spectrometry

Macromolecule Content 

• Total Structure Weight: 2.63 kDa 
• Atom Count: 184 
• Modeled Residue Count: 22 
• Deposited Residue Count: 22 
• Unique protein chains: 1

Macromolecules

Entity ID: 1
Molecule	Chains	Sequence Length	Organism	Details	Image
Site 2 binding peptide IM459N21	A	22	synthetic construct	Mutation(s): 0

Small Molecules

Modified Residues  2 Unique
ID	Chains	Type	Formula	2D Diagram	Parent
AIB	A	L-PEPTIDE LINKING	C4 H9 N O2		ALA
LYN	A	L-PEPTIDE LINKING	C6 H16 N3 O		LYS

Experimental Data & Validation

Experimental Data

• Method: SOLUTION NMR
• Conformers Calculated: 16 
• Conformers Submitted: 16 
• Selection Criteria: all calculated structures submitted 

Structure Validation

Entry History 

& Funding Information

Deposition Data

• Released Date: 2022-11-09 
Deposition Author(s): Lawrence, M.C., Hu, H., Martinez, F.J., Espinosa, J.F.

---

Funding Organization	Location	Grant Number
Not funded		--

Revision History  

• Version 1.0: 2022-11-09
  Type: Initial release